Journal profile · Respiratory System
Experimental Lung Research
ISSN 0190-2148 · eISSN 1521-0499 · Informa Healthcare · UNITED STATES · Bimonthly · Founded 1980
Experimental Lung Research: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.89; fully open access; APC about USD 2,990; median 148 days to acceptance (33 articles, last 24 months); community-reported acceptance: about 25%; 16 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Experimental Lung Research is published by Informa Healthcare and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Neonatal Respiratory Health Research, Inhalation and Respiratory Drug Delivery and Asthma and respiratory diseases, together about 36.1% of its articles. Its main subfields are Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
*Please note that Experimental Lung Research converted to a full Open Access journal from Volume 49 (2023). Previous volumes will continue to provide access through a Pay to Read model Experimental Lung Research publishes original articles in all fields of respiratory tract anatomy, biology, developmental biology, toxicology, and pathology. Emphasis is placed on investigations concerned with molecular, biochemical, and cellular mechanisms of normal function, pathogenesis, and responses to injury. The journal publishes reports on important methodological advances on new experimental modes. Also published are invited reviews on important and timely research advances, as well as proceedings of specialized symposia. Please note, from 2023 the Print ISSN is not in active use as this journal is no longer published in print.
From the journal's Aims & Scope
Research area (LetPub): Respiratory System
Editor-in-chief Mark GiembyczPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Neonatal Respiratory Health ResearchMedicine18.1%
- Inhalation and Respiratory Drug DeliveryMedicine9.8%
- Asthma and respiratory diseasesMedicine8.3%
- Respiratory Support and MechanismsMedicine7.5%
- Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisMedicine6.5%
- Immune Response and InflammationImmunology and Microbiology5.4%
- Chronic Obstructive Pulmonary Disease (COPD) ResearchMedicine5.3%
- Neuroscience of respiration and sleepNeuroscience5.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedCurrent ContentsPublisher website
Other: ProQuest, OCLC, Adis International Ltd., BIOBASE, CABI, EBSCOhost, OCLC Personal Alert (E-mail)
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.89LetPub ·
- Impact factor (publisher) 2025
- 1.9Publisher website ·
- 5-year impact factor (publisher) 2025
- 1.5Publisher website ·
- CiteScore 2026-06
- 3.1LetPub ·
- CiteScore (publisher) 2025
- 3.1Publisher website ·
- SJR 2026-06
- 0.55LetPub ·
- SJR (publisher) 2025
- 0.55Publisher website ·
- SNIP 2026-06
- 0.4LetPub ·
- SNIP (publisher) 2025
- 0.4Publisher website ·
- h-index
- 48LetPub ·
- h-index
- 79OpenAlex ·
- i10-index
- 1,369OpenAlex ·
- 2-year mean citedness
- 2.14OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 16LetPub ·
- Downloads per year (publisher)
- 61,000Publisher website ·
Articles by year OpenAlex count · 2,153 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 13 | 13 | 2 |
| 2025 | 16 | 16 | 19 |
| 2024 | 22 | 22 | 88 |
| 2023 | 17 | 17 | 114 |
| 2022 | 24 | 7 | 142 |
| 2021 | 34 | 3 | 308 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
148 daysMedian, submission to acceptance · P25–P75 116 days – 224 days
- Acceptance to online
- median 17 days (33 articles)
- Submission to online
- median 159 days
- Sample
- 33 articles with submission and acceptance dates (36 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 25%LetPub ·
- Submission to publication (journal-reported)
- about 11 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,990 / GBP 2,392 / EUR 2,875 / AUD 4,165 | Yes | CC BY, CC BY-NC | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open access
Fully open access journal; publishes only open access articles. Model summary
Experimental Lung Research is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers, not just th…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Informa Healthcare
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1980
- ISSN
- 0190-2148
- Electronic ISSN
- 1521-0499
- Latest issue on the website
- Volume 52, Issue 1 (2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Experimental Lung Research
What CAS zone is Experimental Lung Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Experimental Lung Research is in Zone 4 of Medicine, and in Zone 4 of the minor category Respiratory System. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Experimental Lung Research?
The latest impact factor listed by LetPub is 1.89; CiteScore 3.1, h-index 79.
How long does peer review take at Experimental Lung Research?
Based on the dates recorded on 33 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 148 days (interquartile range 116–224 days); authors report an average review time of about 2 months; the community-reported acceptance is “about 25%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Experimental Lung Research?
According to LetPub and DOAJ records, Experimental Lung Research is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, MEDLINE, PubMed and Current Contents; that list has not been checked against each database.
Is Experimental Lung Research open access, and what is the APC?
Experimental Lung Research is a fully open-access journal. APC about USD 2,990.
Sources and updates
The facts on this page come from LetPub, DOAJ, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .